Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial-Reference-Cited by-同舟云学术

Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial

Published:2013-01-07 Issue:2 Volume:33 Page:244-254
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Yim Hyung Joon¹,Seo Yeon Seok²,Yoon Eileen L.¹,Kim Chang Wook³,Lee Chang Don³,Park Sang Hoon⁴,Lee Myung Seok⁴,Park Choong Kee⁵,Chae Hee Bok⁶,Kim Moon Young⁷,Baik Soon Koo⁷,Kim Yun Soo⁸,Kim Ju Hyun⁸,Lee Jung Il⁹,Lee Jin Woo⁹,Hong Sun Pyo¹⁰,Um Soon Ho²

Affiliation:

1. Division of Gastroenterology and Hepatology; Department of Internal Medicine; Korea University Ansan Hospital; Ansan Korea

2. Division of Gastroenterology and Hepatology; Department of Internal Medicine; Korea University Anam Hospital; Seoul Korea

3. Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Catholic University of Korea Uijeongbu St. Mary's Hospital; Uijeongbu Korea

4. Division of Gastroenterology and Hepatology; Department of Internal Medicine; Hallym University Kangnam Sacred Heart Hospital; Seoul Korea

5. Division of Gastroenterology and Hepatology; Department of Internal Medicine; Hallym University Sacred Heart Hospital; Anyang Korea

6. Division of Gastroenterology and Hepatology; Department of Internal Medicine; Chungbuk National University Hospital; Cheongju Korea

7. Division of Gastroenterology and Hepatology; Department of Internal Medicine; Yonsei University Wonju Christian Hospital; Wonju Korea

8. Division of Gastroenterology and Hepatology; Department of Internal Medicine; Gachon University Gil Hospital; Incheon Korea

9. Division of Gastroenterology and Hepatology; Department of Internal Medicine; Inha University Hospital; Incheon Korea

10. GeneMarix Inc.; Yongin Korea

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12036/fullpdf

Reference31 articles.

1. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures;Lavanchy;J Viral Hepat,2004

2. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005;Yim;Hepatology,2006

3. Lamivudine for patients with chronic hepatitis B and advanced liver disease;Liaw;N Engl J Med,2004

4. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B;Lai;Clin Infect Dis,2003

5. Long-term safety of lamivudine treatment in patients with chronic hepatitis B;Lok;Gastroenterology,2003

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B;Gut and Liver;2024-01-12

2. Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B;The Korean Journal of Gastroenterology;2021-01-25

3. Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B;KOR J GASTROENTEROL;2021

4. Tenofovir‐based combination therapy or monotherapy for multidrug‐resistant chronic hepatitis B: Long‐term data from a multicenter cohort study;Journal of Viral Hepatitis;2020-08-20

5. Efficacy and safety of long-term entecavir therapy in a European population;Minerva Gastroenterologica e Dietologica;2018-07